AB Science suspends French masitinib trials after ANSM finds deviations


AB Science SA has halted French trials of its Ph III drug candidate masitinib after regulators uncovered good clinical practice (GCP) and pharmacovigilance deviations in an earlier study.

Sanofi's Montpellier, France site. Image: Google Streetview

Unused €107m pilot plant in France to be demolished, says Sanofi

Image: iStock/Tuomas_Lehtinen

US FDA sends Biocon Bangalore plant 483 with 8 observations

Image: iStock/NiroDesign

UK firms should look to global opportunities to offset Brexit woes, says biotech CEO

Image: iStock/stevanovicigor

Patheon ramping up former Roche site to fulfil demand for Western APIs

Image: iStock/ricardvaque

Apotex expanding US footprint with $184m investment

Image: iStock/Tashatuvango

Allergan's €42m investment boosts Irish manufacturing and jobs

Image: iStock/TheaDesign

GSK on America First: US will not be able to own every part of supply chain

Image: iStock/pcatalin

Cambrex riding high on demand for Western innovator APIs

Image: iStock/chingraph

Biocon wins $68m Malaysian contract for biosimilar insulin and pen supply

More Globalisation